Please login to the form below

Not currently logged in
Email:
Password:

Medtronic heart devices approved

The US Food and Drug Administration has approved a new family of implantable cardiac devices from Medtronic that are intended to reduce the number of inappropriate therapeutic shocks that are delivered

The US Food and Drug Administration has approved a new family of implantable cardiac devices from Medtronic that are intended to improve patients' quality of life by significantly reducing the number of inappropriate therapeutic shocks that are delivered.

The new Protecta portfolio of products, which will begin shipments immediately, includes implantable cardioverter-defibrillators (ICDs) and cardiac resynchronisation therapy-defibrillators (CRT-Ds) that use the company's SmartShock Technology, which is based on six algorithms that recognise life-threatening arrhythmias and deliver therapeutic shocks only when appropriate.

A virtual study conducted by Medtronic based on a statistical model found that the technology results in 98 per cent of patients being free of inappropriate shocks one year after implant and 92 per cent being free of inappropriate shocks five years after implant.

Currently, up to one in five patients with implantable defibrillators may experience inappropriate shocks in response to a benign arrhythmia or electrical noise sensed by the device, according to the company.

29th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics